Annual report for the Association for Accessible Medicines recapping 2012. View press release to learn more about the successful rebrand.
The pages that follow highlight what GPhA and its members accomplished in 2012, the most successful year yet in our history. And while there still is much to do, our vision of being an influential and effective advocate for the interests of our member companies remains the blueprint for our future.
In 2012 we stepped up our close engagement with the FDA to further influence the implementation of two critical laws: the Generic Drug User Fee Act (GDUFA) that was signed into law in July, and the Biologics Price Competition and Innovation Act of 2009 that was part of the Affordable Care Act, both of which are now in the regulatory phase. We also engaged with Congress on GDUFA, appearing half a dozen times before House and Senate Committees to testify on the bill’s benefits to patients and other issues.
Ralph G. NeasPresident & CEO, Generic Pharmaceutical Association
2012 was, in every respect, a banner year for GPhA and its members. In addition to the significant progress we made on an array of key legislative and regulatory fronts, we set records in many operational areas: record annual operating revenues of $11.8 million, up 25 percent over the prior year; record attendance of 623 at our Annual Meeting in Orlando, an increase of 50 percent over the 2010 attendance; record number of company representatives participating on committees and task forces; and record attendance of 700 at our GPhA/FDA Fall Technical Conference.
In July, we took a giant leap forward when President Obama signed into law the Food and Drug Administration Safety and Innovation Act (FDASIA). This legislation will help to ensure one quality standard for all pharmaceuticals utilized in the U.S. by empowering the Food and Drug Administration (FDA) to assure all drug manufacturing facilities that supply the U.S. market are regularly inspected, regardless of whether they are based inside the U.S. or outside our borders, with the end goal of protecting the health and safety of consumers.
Tony Mauro Chairman of the Board, Generic Pharmaceutical Association